FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies By Ogkologos - August 12, 2026 67 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Precision-T study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2023:... June 3, 2023 Over 600 people in England set to benefit from innovative lung... December 1, 2021 First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... July 5, 2021 New Radiation Therapy Won’t Leave Breast Cancer Patients with Unwanted Tattoo... September 13, 2019 Load more HOT NEWS Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II... Coming Soon: Medicare Drug Price Negotiations 4-Year-Old Secretly Told Teacher His Dad Was Sick, And She Donated... Age: the forgotten cancer risk factor?
